Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

JNJ-6368661 characterized as potent, orally active anticoagulant and antithrombotic agent

Dec. 10, 2003

Factor Xa inhibitor from Lilly/Tularik collaboration enters phase II

Dec. 10, 2003

Clinical studies of rhThrombin cleared to commence

Dec. 5, 2003

Ximelagatran demonstrates efficacy in VTE

Dec. 2, 2003

New thrombin receptor antagonists prepared and tested at Schering

Nov. 28, 2003

Trigen identifies new antithrombotic compounds

Nov. 27, 2003

Arixtra receives European approval for extended prophylaxis of VTE

Nov. 21, 2003

Twelve-month data favor transition to bivalirudin as standard treatment

Nov. 21, 2003

Novel factor Xa inhibitors prepared and tested at Merck KGaA

Nov. 18, 2003

Tanabe Seiyaku scientists design novel factor Xa inhibitors

Nov. 17, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Regulatory actions for July 27, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...